Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes

European Heart Journal

Volumn 23, Issue 22, 2002, Pages 1771-1779

  Eikelboom, John W ^a,f   Weitz, J I ^b,c   Budaj, A ^d   Zhao, F ^e   Copland, I ^e   Maciejewski, P ^d   Johnston, M ^b   Yusuf, S ^c,e  

^a ROYAL PERTH HOSPITAL   (Australia)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d GROCHOWSKI HOSPITAL   (Poland)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Aspirin; Clopidogrel; Coagulation; Myocardial infarction; Platelets; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; BIOCHEMICAL MARKER; CLOPIDOGREL; D DIMER; HEPARIN; PADGEM PROTEIN; PLACEBO; PROTHROMBIN; THROMBIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POLAND; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT; STROKE; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANTIGENS; ASPIRIN; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; COHORT STUDIES; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATING FACTOR; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 0036846734     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2000.3234     Document Type: Article

References (31)

1. Fuster V, Badimon L, Badimon JJ, Chesebro J. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50.
2. Hirsh J, Colman RW, Marder VJ, George JN, Clowes AW. Overview of thrombosis and its treatment. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Williams and Wilkins, 2001: 1071-84.
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
4. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST elevation. N Engl J Med 2001; 345: 494-502.
5. Patrono C, Coller B, Dalen JE et al. Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest 2001; 119: 39S-63S.
6. Szczeklik A, Krzanowski M, Gora P, Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. Blood 1992; 80: 2006-11.
7. Kessels H, Beguin S, Andree H, Hemker HC. Measurement of thrombin generation in whole blood: The effect of heparin and aspirin. Thromb Haemost 1994; 72: 78-83.
8. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100: 1667-72.
9. Patrono C, Coller B, Dalen JE et al. Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest 2001; 119: 39S-63S.
10. Rupprecht HJ, Darius H, Borkowski U et al. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation 1998; 97: 1046-52.
11. Moshfegh K, Redondo M, Julmy F et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: Enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 2000; 36: 699-705.
12. The CURE Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000; 21: 2033-41.
13. Ludbrook J. Multiple comparison procedures updated. Clin Exp Pharmacol Physiol 1998; 25: 1032-7.
14. Ardissino D, Merlini PA, Gamba G et al. Thrombin activity and early outcome in unstable angina pectoris. Circulation 1996; 93: 1634-9.
15. Oltrona L, Eisenberg PR, Lasala JM, Sewall DJ, Shelton ME, Winters KJ. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation 1996; 94: 2064-71.
16. Granger CB, Miller JM, Bovill EG et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995; 91: 1929-35.
17. Granger CB, Becker R, Tracy RP et al. Thrombin generation, inhibition, and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: Results from the GUSTO-I Trial. GUSTO-I Coagulation Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1998; 31: 497-505.
18. Rao AK, Sun L, Chesebro JH et al. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. Circulation 1996; 94: 2389-95.
19. Montalescot G, Philippe F, Ankri A et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: Beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 1998; 98: 294-9.
20. Dempfle C-E, Kontny F, Abildgaard U. Predictive value of coagulation markers concerning clinical outcome 90 days after acute myocardial infarction. Thromb Haemost 1999; 81: 701-4.
21. Ernofsson M, Strekerud F, Toss H, Abildgaard U, Wallentin L, Siegbahn A. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost 1998; 79: 491-4.
22. Gold HK, Torres FW, Garabedian HD et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993; 21: 1039-47.
23. Flather M, Weitz J, Yusuf S et al., for the OASIS (Organization to Assess Strategies for Ischaemic Syndromes) Pilot Study Investigators. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. Eur Heart J 2000; 21: 1473-81.
24. Merlini PA, Bauer KA, Oltrona L et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-8.
25. Xu DY, Zhae SP, Peng WP. Elevated plasma levels of soluble P-selectin in patients with acute myocardial infarction and unstable angina. An inverse link to lipoprotein (a). Int J Cardiol 1998; 64: 253-8.
26. Gurbel PA, Kereiakes DJ, Dalesandro MR, Bahr RD, O'Connor CM, Serebruany VL. Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. Am Heart J 2000; 139: 320-8.
27. Shimomura H, Ogawa H, Arai H et al. Serial changes in plasma levels of soluble P-selectin in patients with acute myocardial infarction. Am J Cardiol 1998; 81: 397-400.
28. Ikeda H, Takajo Y, Ichiki K et al. Increased soluble forms of P-selectin in patients with unstable angina. Circulation 1995; 92: 1693-6.
29. Gurbel PA, Kereiakes DJ, Serebruany VL. Soluble P-selectin is not a surrogate marker for platelet P-selectin. Evidence from a multicenter chest pain study group. J Thromb Thrombolysis 2000; 10: 15-22.
30. Kleiman NS, Tracy RP, Talley JD et al. Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction. J Thromb Thrombolysis 2000; 9: 5-12.
31. Ardissino D, Merlini P, Repetto A et al. Coagulation activation during abciximab infusion in patients with acute coronary syndromes: GUSTO IV haematological substudy. Eur Heart J 2001; 22 (Suppl): 592.